research use only
Cat.No.S2394
| Related Targets | Dehydrogenase HSP Transferase PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase |
|---|---|
| Other P450 (e.g. CYP17) Inhibitors | Apigenin Baicalein Diosmetin Alizarin Sodium Danshensu Naringin Benzbromarone Orteronel Isosilybin Danshensu |
|
In vitro |
DMSO
: 54 mg/mL
(198.34 mM)
Ethanol : 54 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 272.25 | Formula | C15H12O5 |
Storage (From the date of receipt) | 3 years -20°C powder (seal) |
|---|---|---|---|---|---|
| CAS No. | 480-41-1 | Download SDF | Storage of Stock Solutions | Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt. | |
| Synonyms | NSC 34875, S-Dihydrogenistein, NSC 11855, Salipurol | SMILES | C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O | ||
Read more about storage stability CAS number SMILES
| Targets/IC50/Ki |
CYP1A2
|
|---|---|
| In vitro |
Naringenin is a flavonoid that is considered to have a bioactive effect on human health as antioxidant, free radical scavenger, anti-inflammatory, carbohydrate metabolism promoter, and immune system modulator. This compound is the predominant flavanone in grapefruit. This substance has also been shown to reduce oxidative damage to DNA in vitro. It found in grapefruit juice has been shown to have an inhibitory effect on the human cytochrome P450 isoform CYP1A2, which can change pharmacokinetics in a human (or orthologous) host of several popular agents in an adverse manner, even resulting in carcinogens of otherwise harmless substances.
|
| In vivo |
Intragastrically administered Naringenin (50 mg/kg) induces a significant decrease in plasma glucose in normoglycaemic and non-insulin-dependent diabetes mellitus (NIDDM) rat models. LD50: Mice >5g/kg; Rats >5g/kg.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2026-07-30)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06612762 | RECRUITING | Bone Fractures |
Shahid Beheshti University of Medical Sciences |
2024-11-03 | |
| NCT05073523 | Completed | Healthy |
Chalmers University of Technology |
2021-09-27 | Not Applicable |
| NCT04697355 | COMPLETED | Energy Expenditure; Safety Issues; Glucose Metabolism |
Pennington Biomedical Research Center |
2021-04-19 | |
| NCT04731987 | Active not recruiting | Metabolic Syndrome|Vascular Compliance|Predisposition to Cardiovascular Disease |
University Hospital Clermont-Ferrand|UMR 1019 Unité de Nutrition Humaine INRAE Auvergne-Rhône Alpes Center|Department of Beverage Research Chair of analysis and technology of plant-based foods Geisenheim University|European Fruit Juice Association (AIJN) |
2021-02-24 | Not Applicable |
| NCT03582553 | COMPLETED | Safety Issues; Pharmacokinetics |
Pennington Biomedical Research Center |
2018-05-25 | EARLY_PHASE1 |
| NCT03582553 | Completed | Safety Issues|Pharmacokinetics |
Pennington Biomedical Research Center|Louisiana Clinical and Translational Science Center |
2018-05-25 | Early Phase 1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.